(7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate

We are (7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate CAS:179688-53-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate
CAS.NO:179688-53-0
Synonyms:6-Acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one
3,4-dihydro-4-oxo-6-acetyloxy-7-methoxy-quinazoline
Molecular Formula:C11H10N2O4
Molecular Weight:234.20800
 
Physical and Chemical Properties:
Density:1.39
Melting point:26ºC
Boiling point:452.391ºC
Flash point:227.398ºC
Index of Refraction:1.612
 
Specification:
Appearance:Off-white to grey to brownish grey powder
Purity(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Gefitinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.

(7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate


Related News: The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.106266-04-0 The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.1,1-dicloropinacolina CAS:22591-21-5 Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.

Related Products
Product Name
(3R,4S,5R,6R)-2-(dichloromethyl)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-ol View Details
2,4,6-TRICHLOROPHENYL ISOTHIOCYANATE View Details
3-Fluoro-2-methylbenzoic acid View Details
1-Chloro-5-iodopentane manufacturer Methyl 2-iodobenzoate manufacturer Ethyl 3-(4-(methylamino)-3-nitro-N-(pyridin-2-yl)benzamido)propanoate manufacturer 3-Amino-5-Chlorobenzotrifluoride manufacturer curcumin manufacturer